Free Trial

Fate Therapeutics (FATE) Competitors

Fate Therapeutics logo
$1.46 -0.09 (-5.52%)
As of 01:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FATE vs. RZLT, NRIX, DAWN, AKBA, OLMA, TYRA, TERN, TBPH, ARVN, and ERAS

Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Rezolute (RZLT), Nurix Therapeutics (NRIX), Day One Biopharmaceuticals (DAWN), Akebia Therapeutics (AKBA), Olema Pharmaceuticals (OLMA), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), Theravance Biopharma (TBPH), Arvinas (ARVN), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.

Fate Therapeutics vs. Its Competitors

Fate Therapeutics (NASDAQ:FATE) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Rezolute has lower revenue, but higher earnings than Fate Therapeutics. Rezolute is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$13.63M12.31-$186.26M-$1.45-1.00
RezoluteN/AN/A-$74.41M-$0.97-8.85

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 5.5% of Fate Therapeutics shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Fate Therapeutics currently has a consensus price target of $3.30, indicating a potential upside of 126.80%. Rezolute has a consensus price target of $14.50, indicating a potential upside of 68.86%. Given Fate Therapeutics' higher probable upside, research analysts plainly believe Fate Therapeutics is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Rezolute
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

In the previous week, Fate Therapeutics had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Fate Therapeutics and 1 mentions for Rezolute. Rezolute's average media sentiment score of 0.50 beat Fate Therapeutics' score of 0.34 indicating that Rezolute is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rezolute
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rezolute has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,025.05%. Fate Therapeutics' return on equity of -50.95% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-2,025.05% -50.95% -36.76%
Rezolute N/A -65.03%-58.86%

Fate Therapeutics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500.

Summary

Fate Therapeutics and Rezolute tied by winning 8 of the 16 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FATE vs. The Competition

MetricFate TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$167.81M$3.41B$6.08B$10.51B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-1.0022.5084.1027.01
Price / Sales12.31481.27607.14130.56
Price / CashN/A46.9737.8662.13
Price / Book0.5210.4112.236.56
Net Income-$186.26M-$52.47M$3.32B$276.88M
7 Day Performance-11.01%1.72%0.46%0.68%
1 Month Performance53.16%13.86%7.73%3.86%
1 Year Performance-54.81%12.07%70.73%34.96%

Fate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
4.1822 of 5 stars
$1.46
-5.5%
$3.30
+126.8%
-52.0%$167.81M$13.63M-1.00550
RZLT
Rezolute
2.4649 of 5 stars
$8.07
-2.4%
$14.50
+79.7%
+79.2%$751.15MN/A-8.3240
NRIX
Nurix Therapeutics
1.8875 of 5 stars
$9.72
-0.4%
$27.93
+187.3%
-61.1%$750.38M$54.55M-3.27300Trending News
Analyst Forecast
Analyst Revision
DAWN
Day One Biopharmaceuticals
3.1376 of 5 stars
$7.19
-0.7%
$25.29
+251.7%
-50.2%$741.61M$131.16M-7.5760Gap Down
AKBA
Akebia Therapeutics
3.5941 of 5 stars
$2.78
+1.1%
$6.75
+142.8%
+119.5%$729.15M$160.18M-16.35430
OLMA
Olema Pharmaceuticals
3.0003 of 5 stars
$10.75
+1.7%
$23.33
+117.1%
-22.0%$725.47MN/A-5.4370
TYRA
Tyra Biosciences
2.5207 of 5 stars
$14.36
+6.2%
$31.86
+121.8%
-42.7%$720.58MN/A0.0020
TERN
Terns Pharmaceuticals
4.0812 of 5 stars
$8.20
+0.6%
$15.49
+88.9%
+12.5%$713.22MN/A-7.8840News Coverage
Analyst Forecast
TBPH
Theravance Biopharma
3.2392 of 5 stars
$13.92
-0.5%
$23.00
+65.2%
+61.4%$704.55M$64.38M58.00110News Coverage
ARVN
Arvinas
3.5345 of 5 stars
$9.80
+3.6%
$16.29
+66.2%
-65.2%$694.53M$263.40M-9.70420Analyst Downgrade
Gap Down
High Trading Volume
ERAS
Erasca
2.8724 of 5 stars
$2.40
-0.4%
$3.71
+54.8%
-11.2%$683.65MN/A-5.33120Analyst Forecast

Related Companies and Tools


This page (NASDAQ:FATE) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners